Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T, Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M, Nakagawa H, Nagano H, Takami T, Yamasaki T. Saeki I, et al. Among authors: oono t. Hepatol Int. 2023 Oct;17(5):1289-1299. doi: 10.1007/s12072-023-10488-y. Epub 2023 Apr 25. Hepatol Int. 2023. PMID: 37186217
A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
Ishikawa T, Egusa M, Fujioka T, Nishiyama N, Kawamoto D, Sasaki R, Nishimura T, Tanabe N, Oono T, Saeki I, Takami T. Ishikawa T, et al. Among authors: oono t. J Gastroenterol. 2023 Mar;58(3):246-256. doi: 10.1007/s00535-022-01947-8. Epub 2022 Dec 30. J Gastroenterol. 2023. PMID: 36583759
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S, Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano K, Nagano H, Takami T. Yamauchi Y, et al. Among authors: oono t. Hepatol Res. 2023 Jul;53(7):681-686. doi: 10.1111/hepr.13894. Epub 2023 Mar 14. Hepatol Res. 2023. PMID: 36826420
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S, Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T. Tanabe N, et al. Among authors: oono t. Cancers (Basel). 2023 May 26;15(11):2927. doi: 10.3390/cancers15112927. Cancers (Basel). 2023. PMID: 37296889 Free PMC article.
Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y. Murakami M, et al. Among authors: oono t. J Gastroenterol. 2023 Jun;58(6):586-597. doi: 10.1007/s00535-023-01987-8. Epub 2023 Apr 26. J Gastroenterol. 2023. PMID: 37099152
Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study.
Miyagahara T, Fujimori N, Ueda K, Takamatsu Y, Matsumoto K, Teramatsu K, Takaoka T, Suehiro Y, Shimokawa Y, Omori K, Niina Y, Tachibana Y, Akashi T, Oono T, Ogawa Y. Miyagahara T, et al. Among authors: oono t. Asia Pac J Clin Oncol. 2023 Aug;19(4):533-541. doi: 10.1111/ajco.13903. Epub 2022 Dec 7. Asia Pac J Clin Oncol. 2023. PMID: 36478079
169 results